文献速递心力衰竭与心肌病高血压

慢性肾病患者ARB与CCB的心衰及肾脏结局比较

Heart failure and renal outcomes with angiotensin receptor blockers compared with calcium channel blockers in patients with chronic kidney disease: a target trial emulation.
PubMed 文献 · Heart · 2026-06-23

结果提示ARB策略与较低的终末期肾病和全因死亡风险相关,心衰住院风险方向性偏低但无统计学意义。

要点

  • ARB策略与较低的终末期肾病进展风险相关(HR 0.533,95%CI 0.317–0.898)。
  • ARB策略与较低的全因死亡风险相关(HR 0.825,95%CI 0.706–0.963)。
  • 心衰住院风险方向性偏低但无统计学意义(HR 0.871,95%CI 0.751–1.011)。

核心结论

  • 在慢性肾病患者中,以ARB为基础的降压策略与较低的肾衰竭和全因死亡风险相关。
  • 心衰住院风险方向性偏低但统计不确定,心肌梗死与卒中未见一致差异。
  • 观察性设计限制因果解释。

研究设计与样本

  • 采用日本全国医保理赔与健康体检数据的目标试验模拟研究,时间范围为2014年4月至2024年9月。
  • 序贯嵌套新使用者试验设计,采用1个月导入期方法比较ARB为基础与CCB为基础的降压策略。
  • 采用离散时间比例风险模型并结合治疗与删失逆概率加权估计意向性治疗效应,并考虑竞争风险。

主要发现

  • 心衰住院:HR 0.871,95%CI 0.751至1.011。
  • 终末期肾病进展:HR 0.533,95%CI 0.317至0.898。
  • 全因死亡:HR 0.825,95%CI 0.706至0.963。
  • 心肌梗死或卒中未见一致差异。

临床怎么用

  • 在慢性肾病患者选择降压策略时,可考虑以ARB为基础的治疗以降低肾衰竭与死亡风险。
  • 心衰住院获益尚不确定,不应据此单独作为选择ARB的依据。
  • 需结合患者个体情况与观察性证据的局限进行共同决策。

局限性

  • 观察性目标试验模拟设计,因果解释受限。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension is highly prevalent among patients with chronic kidney disease (CKD) and contributes substantially to cardiovascular complications and progression of kidney disease. Although angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) are widely used antihypertensive agents in CKD, comparative evidence regarding their long-term effects on clinically important cardiorenal outcomes remains limited. METHODS: We conducted a target trial emulation using nationwide-scale healthcare claims and health check-up data in Japan between April 2014 and September 2024. We emulated sequentially nested new-user trials and used a 1-month induction-period approach to compare ARB-based versus CCB-based antihypertensive treatment strategies. Intention-to-treat effects were estimated using discrete-time proportional hazards models with inverse probability of treatment and censoring weighting, accounting for competing risks. RESULTS: Among 12 978 patients with CKD (4524 initiating ARB-based therapy and 8454 initiating CCB-based therapy), ARB-based strategies were associated with a directionally lower but not statistically significant risk of heart failure hospitalisation (HR 0.871, 95% CI 0.751 to 1.011). ARB-based therapy was also associated with lower risks of progression to end-stage renal disease (HR 0.533, 95% CI 0.317 to 0.898) and all-cause mortality (HR 0.825, 95% CI 0.706 to 0.963). No consistent differences were observed for myocardial infarction or stroke. CONCLUSIONS: In this nationwide target trial emulation, ARB-based antihypertensive strategies were associated with lower risks of kidney failure and all-cause mortality, with a directionally lower but statistically uncertain risk of heart failure hospitalisation. These findings suggest that ARB-based antihypertensive strategies may confer clinically relevant cardiorenal benefits compared with CCB-based strategies in patients with CKD, although causal interpretation remains limited by the observational design.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Noma, Kurita, Fukuma, et al. Heart failure and renal outcomes with angiotensin receptor blockers compared with calcium channel blockers in patients with chronic kidney disease: a target trial emulation. Heart. 2026. PMID: 42336624. doi:10.1136/heartjnl-2026-328193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。